Nuvectra® is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. Visit the Nuvectra website at www.nuvectramed.com.
Company profile
Ticker
NVTR, NVTRQ
Exchange
Website
CEO
Fred B. Parks
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Qig Group, LLC
SEC CIK
Corporate docs
NVTR stock data
Latest filings (excl ownership)
8-K
Regulation FD Disclosure
20 Apr 20
8-K
Monthly Operating Report
25 Mar 20
8-K
Other Events
16 Mar 20
8-K
Monthly Operating Report
13 Feb 20
8-K
Other Events
31 Jan 20
8-K
Monthly Operating Report
15 Jan 20
8-K
Monthly Operating Report
31 Dec 19
25-NSE
Exchange delisting
17 Dec 19
8-K
Cost Associated with Exit or Disposal Activities
22 Nov 19
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
14 Nov 19
Latest ownership filings
SC 13G/A
GILDER GAGNON HOWE & CO LLC
16 Feb 21
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G
Nuvectra Corp
14 Feb 20
4
DAVID D JOHNSON
26 Dec 19
4
KENNETH G HAWARI
26 Dec 19
4
Anthony P Bihl III
26 Dec 19
4
Jennifer Kosharek
16 Dec 19
4
Benjamin Tranchina
9 Dec 19
4
KENNETH G HAWARI
4 Dec 19
4
Jennifer Kosharek
25 Nov 19
Institutional ownership, Q3 2021
4.2% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 754.87 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Integrated Core Strategies | 754.87 k | $0.00 |